-4.2 | | GPR75 | 'RRx-1; 20 micromolar' vs 'none' | compound | RNA-seq of Huh7 cell after G6PD enzyme activity inhibitor RRx-1 treated with 20μM concentrations for 24h |
-3.5 | | GPR75 | 'NLRC4-Macrophage Activation Syndrome; prior to anakinra treatment' vs 'normal' | disease, treatment | An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome |
-3 | | GPR75 | 'breast carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-2.7 | | GPR75 | 'CD3/CD28 beads' vs 'none' in 'none' | stimulus, xenograft | RNA-Seq of T cells sorted from human PBMCs, or from T cells stimulated with CD3/CD28 beads for 4 days, or from the spleen of NSG or NSG-HLA-A2/HHD mice, 7 days after transplantation with human PBMCs |
-2.7 | | GPR75 | 'pancreatic adenocarcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
2.6 | | GPR75 | 'anti-m6A' vs 'none' | treatment | Transcription profiling by high throughput sequencing in identification of m6A modified sequences in HepG2 cells |
-2.5 | | GPR75 | 'doxorubicin; 5 micomolar and T0901317; 5 micromolar' vs 'none' | compound | LXR mediated-signalling protects human hair follicles against doxorubicin-induced toxicity ex vivo |
-2.3 | | GPR75 | 'non-triple-negative breast cancer; breast carcinoma' vs 'normal' | clinical information, disease | RNA-seq of 17 breast tumor samples of three different subtypes and normal human breast organoids samples |
-2.2 | | GPR75 | 'triple-negative breast cancer; breast carcinoma' vs 'normal' | clinical information, disease | RNA-seq of 17 breast tumor samples of three different subtypes and normal human breast organoids samples |
-2.2 | | GPR75 | 'colorectal carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
2.1 | | GPR75 | 'GATA6 R456C/+; Patient A' vs 'wild type genotype; H9' in 'definitive endoderm cell' | cell line, cell type, genotype, individual | RNA-seq of definitive endoderm and pancreatic progenitor cells derived in vitro from human pluripotent stem cells in order to study the role of transcription factor GATA6 in human pancreas development |
2.1 | | GPR75 | 'Braf activated' vs 'untreated' | treatment | Expression data from Control, Uninfected and BRAF infected cells |
-1.9 | | GPR75 | 'HER2 Positive Breast Carcinoma; breast carcinoma' vs 'normal' | clinical information, disease | RNA-seq of 17 breast tumor samples of three different subtypes and normal human breast organoids samples |
-1.9 | | GPR75 | 'lapatinib; 500 nanomolar; 1 day' vs 'dimethyl sulfoxide; 1 day' | compound, time | RNA-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib |
-1.9 | | GPR75 | 'gefitinib; 24 hour' vs 'none; 2 hour' | compound, time | RNA-seq of A431 cell line after gefitinib treatment |
-1.8 | | GPR75 | 'Sorafenib; 5 micromolar' vs 'vehicle' in 'HuH-7' | cell line, compound | RNA-seq of human hepatocellular carcinoma cell line Huh7 and immortalized hepatocyte cell line THLE5B treated with experimental compound AD80, Sorafenib, and vehicle for 24 hours |
-1.8 | | GPR75 | 'progenitor cell of endocrine pancreas' vs 'definitive endoderm cell' in 'GATA6 R456C/+; Patient A" | cell line, cell type, genotype, individual | RNA-seq of definitive endoderm and pancreatic progenitor cells derived in vitro from human pluripotent stem cells in order to study the role of transcription factor GATA6 in human pancreas development |
1.8 | | GPR75 | 'Braf activated' vs 'empty vector' | treatment | Expression data from Control, Uninfected and BRAF infected cells |
-1.8 | | GPR75 | 'hepatobiliary carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
1.7 | | GPR75 | '7 hour' vs '0 hour' in 'MDA-MB-231' | cell line, time | Transcription profiling by high throughput sequencing in MDA-MB-231 and MDA-LM2 cell lines |
1.7 | | GPR75 | 'KCl' vs 'none' in 'NEAT1 antisense oligonucleotide' | RNA interference, stimulus | RNA-seq of NEAT1 knockdown in neuronal excitability |
-1.7 | | GPR75 | 'KLF17 overexpression' vs 'wild type phenotype' at '4 day' | phenotype, time | RNA-seq of hESCs overexpressing inducible KLF17 versus uninduced controls. |
1.6 | | GPR75 | 'poly(I:C); 25 microgram per milliliter' vs 'none' in 'none; none' | compound, infect, stimulus | RNA-seq of H1N1 infected monocyte-derived dendritic cells (MoDC), stimulated with single-stranded oligonucleotides (ssON) and/or Poly I:C. |
-1.6 | | GPR75 | '3 h DRB 8 min 4sU' vs 'untreated' | treatment | 4sUDRB-seq: measuring transcription elongation and initiation genomewide |
-1.6 | | GPR75 | 'KLF17 overexpression' vs 'wild type' at '5 day' | phenotype, time | RNA-seq of hESCs undergoing primed to naive-like resetting via exogenous KLF17 overexpression |
1.5 | | GPR75 | 'KCl' vs 'none' in 'scrambled antisense oligonucleotide' | RNA interference, stimulus | RNA-seq of NEAT1 knockdown in neuronal excitability |
1.5 | | ENSG00000119737 | 'lipopolysaccharide' vs 'none' in 'normal' | disease, stimulus | A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis [RNA-Seq] |
1.5 | | GPR75 | 'apical radial glial cell' vs 'neuron' | cell type | Transcription profiling by high throughput sequencing of the developing human cortex |
1.5 | | GPR75 | 'Cisplatin' vs 'None' in 'A2780; Hypoxia' | cell line, compound, growth condition | Analysis of gene expression changes in response to hypoxia and/or cisplatin in A2780 and A2780cis cells |
-1.5 | | GPR75 | ' neural stem cell' vs 'induced pluripotent stem cell' in 'normal' | cell type, disease | Human iPSC-Derived Cerebellar Neurons from a Patient with Ataxia-Telangiectasia Reveal Disrupted Gene Regulatory Networks |
1.4 | | ENSG00000119737 | 'Growth Medium' vs 'none' in 'systemic-onset juvenile idiopathic arthritis' | disease, stimulus | A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis [RNA-Seq] |
1.4 | | GPR75 | 'neurotrophin-4' vs 'none' at '2 hour' | sampling time point, stimulus | RNA-seq of human neurons derived from H9 embryonic stem cell lines treated with BDNF, TrkB agonist ZEB 85 or NT4 against untreated controls |
1.4 | | ENSG00000119737 | 'lipopolysaccharide' vs 'none' in 'systemic-onset juvenile idiopathic arthritis' | disease, stimulus | A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis [RNA-Seq] |
-1.4 | | GPR75 | 'PLX4720; 1 micromolar' vs 'none' | compound | RNA-seq of the human melanoma cell-line A375P treated with the BRAF inhibitor PLX4720 and a DMSO control |
-1.4 | | GPR75 | 'relapsing-remitting multiple sclerosis' vs 'normal' | disease | RNA-seq of peripheral blood from healthy controls and established relapsing-remitting multiple sclerosis patients |
-1.3 | | GPR75 | '1 day' vs '0 day' | time | RNA-Seq characterization of human H1-derived NPC differentiation timecourse |
1.3 | | GPR75 | 'definitive endoderm differentiated from H9 stem cells' vs 'Undifferentiated H9 Stem Cells' | cell type | Transcriptional Profiling of human pluripotent stem cells and and derived tissues |
1.3 | | GPR75 | '7 hour' vs '0 hour' in 'MDA-LM2' | cell line, time | Transcription profiling by high throughput sequencing in MDA-MB-231 and MDA-LM2 cell lines |
-1.3 | | GPR75 | 'Hypoxia' vs 'Normoxia' in 'A2780; None' | cell line, compound, growth condition | Analysis of gene expression changes in response to hypoxia and/or cisplatin in A2780 and A2780cis cells |
-1.3 | | GPR75 | 'cisplatin; 100 micromolar' vs 'none' in 'scrambled siRNA' | RNA interference, compound | RNA-seq of human head and neck cancer cell line SQD9 knock-out for TMEM45A exposed to cisplatin |
1.3 | | GPR75 | 'ssON; 0.5 micromolar' vs 'none' in 'none; none' | compound, infect, stimulus | RNA-seq of H1N1 infected monocyte-derived dendritic cells (MoDC), stimulated with single-stranded oligonucleotides (ssON) and/or Poly I:C. |
-1.3 | | GPR75 | 'non-small cell lung carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-1.2 | | GPR75 | '11 day' vs '0 day' | time | RNA-Seq characterization of human H1-derived NPC differentiation timecourse |
1.2 | | GPR75 | 'blood alcohol content 0.08%' vs 'control' in 'time point 3' | sampling time point, treatment | Microarray characterization of gene expression changes in blood during acute ethanol exposure |
1.2 | | GPR75 | 'brain-derived neurotrophic factor' vs 'none' at '2 hour' | sampling time point, stimulus | RNA-seq of human neurons derived from H9 embryonic stem cell lines treated with BDNF, TrkB agonist ZEB 85 or NT4 against untreated controls |
1.2 | | ENSG00000119737 | 'Growth Medium' vs 'none' in 'normal' | disease, stimulus | A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis [RNA-Seq] |
1.2 | | GPR75 | 'heat shock' vs 'untreated' | growth condition | RNA-seq analysis of U2OS cells exposed to heat stress |
1.2 | | GPR75 | 'induced pluripotent stem cell' vs 'fibroblast of dermis' in 'normal' | cell type, disease | Klinefelter syndrome derived hiPSCs show similar XCI behavior as female hPSCs |
-1.2 | | GPR75 | '180 days after left ventricular assist device placement' vs 'control' | treatment | Identification of differentially expressed transcripts and pathways one week and six months following implant of left ventricular devices |
-1.2 | | GPR75 | 'doxorubicin; 5 micromolar' vs 'none' | compound | LXR mediated-signalling protects human hair follicles against doxorubicin-induced toxicity ex vivo |
-1.2 | | GPR75 | '6 hour' vs '0 hour' in 'MCF-10A' | cell line, time | Knock-in of PIK3CA-H1047R into MCF-10A |
-1.1 | | GPR75 | 'injected in NSG mouse' vs 'none' in 'none' | stimulus, xenograft | RNA-Seq of T cells sorted from human PBMCs, or from T cells stimulated with CD3/CD28 beads for 4 days, or from the spleen of NSG or NSG-HLA-A2/HHD mice, 7 days after transplantation with human PBMCs |
1.1 | | GPR75 | '501Mel; shBRG1 knockdown' vs '501Mel; control' | cell line, phenotype | BRG1 recruitment by transcription factors MITF and SOX10 defines a specific configuration of regulatory elements in the melanocyte lineage (RNA-seq) |
1.1 | | GPR75 | 'Human betacoronavirus 2c EMC/2012' vs 'mock' at '24 hour' | infect, time | Transcription profiling of human bronchial epithelial cell line Calu-3 2B4 infected with Human Coronavirus EMC 2012 |
-1.1 | | GPR75 | 'USP22 knockdown by siRNA' vs 'non-targetting siRNA' | RNA interference | mRNA-seq of HCT116 USP22 knockdown cells |
1.1 | | GPR75 | '5 micromolar CG-1521' vs 'vehicle' in 'SUM190PT' | cell line, compound | Expression Profiling of Inflammatory Breast Cancer Cells Treated with the Novel Histone Deacetylase Inhibitor, CG-1521 |
-1.1 | | GPR75 | 'cultured with 3D BPH-1 epithelial acini' vs 'cultured without epithelial acini' | growth condition | Transcription profiling by array of human stromal cells cultured with or without 3D BPH-1 prostate epithelial cells |
-1.1 | | GPR75 | 'Influenza A virus (A/California/07-00001/2009(H1N1))' vs 'none' in 'poly(I:C); 25 microgram per milliliter; none' | compound, infect, stimulus | RNA-seq of H1N1 infected monocyte-derived dendritic cells (MoDC), stimulated with single-stranded oligonucleotides (ssON) and/or Poly I:C. |
1.1 | | GPR75 | '10 nanomolar 17beta-estradiol and 5 micromolar CG-1521' vs 'vehicle' in 'SUM190PT' | cell line, compound | Expression Profiling of Inflammatory Breast Cancer Cells Treated with the Novel Histone Deacetylase Inhibitor, CG-1521 |
-1.1 | | GPR75 | 'cisplatin; 100 micromolar' vs 'none' in 'TMEM45A knockdown by siRNA' | RNA interference, compound | RNA-seq of human head and neck cancer cell line SQD9 knock-out for TMEM45A exposed to cisplatin |
1.1 | | GPR75 | 'esophageal adenocarcinoma' vs 'Barrett’s esophagus; non-dysplastic' | disease, disease staging | Whole transcriptome profiling of Esophageal adenocarcinoma and Barrett's |
1.1 | | GPR75 | 'schizophrenia' vs 'normal' in 'Brodmann (1909) area 24' | disease, organism part | RNA-seq of three brain regions from schizophrenia and bipolar disorder patients and psychiatrically normal individuals |
1 | | GPR75 | '4 hour' vs '0 hour' in 'MDA-MB-231' | cell line, time | Transcription profiling by high throughput sequencing in MDA-MB-231 and MDA-LM2 cell lines |
1 | | GPR75 | '154; 1 micromolar' vs 'DMSO' | compound | Development of a small molecule for treatment of castration resistant prostate cancer via androgen receptor and IL6/STAT3 pathways |
1 | | GPR75 | 'blood alcohol content 0%' vs 'control' in 'time point 1' | sampling time point, treatment | Microarray characterization of gene expression changes in blood during acute ethanol exposure |
1 | | GPR75 | 'blood alcohol content 0.04%declining' vs 'control' in 'time point 4' | sampling time point, treatment | Microarray characterization of gene expression changes in blood during acute ethanol exposure |
1 | | GPR75 | 'ochratoxin A; 130 nanomolar' vs 'none' at '1 day' | compound, time | Microarray mRNA data of RPTEC/TERT1 cells exposed to nephrotoxic chemicals ochratoxin A and potassium bromate |
1 | | GPR75 | 'tumor necrosis factor alpha' vs 'none' in 'brain microvascular endothelial cell; co-culture' | cell type, growth condition, stimulus | Reactive astrocytes transduce blood-brain barrier inflammation through a TNFα-STAT3 signaling axis and secretion of alpha 1-antichymotrypsin |
1 | | ENSG00000119737 | 'T3; 100 nanomolar' vs 'none' in 'derived neural cell; correction to MCT8[wt]' | cell type, compound, genotype | RNA-seq analysis of MCT8-deficient and healthy control brain microvascular endothelial cells (BMECs) and neural cells |
1 | | GPR75 | 'SPRY1 knockdown by siRNA' vs 'none' | RNA interference | Loss of Spry1 reduces growth of BRAFV600E-mutant cutaneous melanoma and improves response to targeted therapy |
-1 | | GPR75 | 'human intestinal organoids derived from H9 stem cells' vs 'Undifferentiated H9 Stem Cells' | cell type | Transcriptional Profiling of human pluripotent stem cells and and derived tissues |
-1 | | GPR75 | 'sulforaphane; prostate carcinoma' at '6 hour' vs 'sulforaphane; normal' at '6 hour' | compound, disease, time | Genome-wide transcriptome analysis of the dietary chemopreventive phytochemical sulforaphane on normal and prostate cancer cells. |
1 | | GPR75 | 'astrocytic glioma' vs 'normal' | disease | gene expression profiling of three type of grade II gliomas |
-1 | | GPR75 | 'GATA6 c.618_619insTGCA/+' vs 'wild type genotype' in 'H9; progenitor cell of endocrine pancreas' | cell line, cell type, genotype, individual | RNA-seq of definitive endoderm and pancreatic progenitor cells derived in vitro from human pluripotent stem cells in order to study the role of transcription factor GATA6 in human pancreas development |
-1 | | GPR75 | 'wild type; tunicamycin' vs 'wild type; control' | genotype, treatment | Induction of ER stress in HCT116 colon cancer cells |
-1 | | GPR75 | 'lapatinib; 500 nanomolar; 7 day' vs 'dimethyl sulfoxide; 1 day' | compound, time | RNA-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib |
